CureVac NV (5CV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CureVac NV (5CV) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€29.86 Million ≈ $34.91 Million USD) by net assets (€871.23 Million ≈ $1.02 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CureVac NV net asset quality index to measure how much of total assets are equity-financed.
CureVac NV - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how CureVac NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 5CV cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CureVac NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CureVac NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
0.042x |
|
Neurones
PA:NRO
|
0.144x |
|
Whirlpool China Co Ltd
SHG:600983
|
0.057x |
|
Apacer Technology Inc
TW:8271
|
0.014x |
|
Sana Biotechnology Inc
NASDAQ:SANA
|
-0.313x |
|
Nsfocus Information Technology Co Ltd
SHE:300369
|
-0.005x |
|
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
|
-0.021x |
|
Cementos Pacasmayo SAA ADR
NYSE:CPAC
|
0.032x |
Annual Cash Flow Conversion Efficiency for CureVac NV (2018–2024)
The table below shows the annual cash flow conversion efficiency of CureVac NV from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see 5CV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €696.61 Million ≈ $814.41 Million |
€101.85 Million ≈ $119.07 Million |
0.146x | +128.21% |
| 2023-12-31 | €516.94 Million ≈ $604.36 Million |
€-267.89 Million ≈ $-313.19 Million |
-0.518x | +3.44% |
| 2022-12-31 | €533.25 Million ≈ $623.43 Million |
€-286.18 Million ≈ $-334.57 Million |
-0.537x | +49.60% |
| 2021-12-31 | €688.48 Million ≈ $804.90 Million |
€-733.13 Million ≈ $-857.10 Million |
-1.065x | -245.00% |
| 2020-12-31 | €711.35 Million ≈ $831.64 Million |
€522.40 Million ≈ $610.74 Million |
0.734x | -63.85% |
| 2019-12-31 | €-42.80 Million ≈ $-50.04 Million |
€-86.96 Million ≈ $-101.67 Million |
2.032x | +187.96% |
| 2018-12-31 | €32.08 Million ≈ $37.51 Million |
€-74.11 Million ≈ $-86.64 Million |
-2.310x | -- |
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more